Additionally, incorporation of molecular criteria has been proposed, including detection of NF2 gene variants in the peripheral blood or in multiple tumors, and exclusion of patients with lesions harboring mutations in LZTR1 which are associated with schwannomatosis [43]. This evidence concerns the gene NF2 and schwannomatosis.